Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
SK HYNIX INC (SKHY)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-11-04
$143.07-5.12%
Close 2026-11-04 · 1-day change
NASDAQInformation TechnologySemiconductorsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
46321.49 → 53281.43 EPS · FY ending Dec 31, 2027 · 6 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 6; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for SKHY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital expenditures effectively | A supporting condition in SK HYNIX INC's published investment case. The stated target is capex growth <= 10% YoY. | Intact | capex growth exceeds 15% YoY | Capital expenditures: KRW 10,671B FY2026-Q2; GAAP. Published target: capex growth <= 10% YoY. Annual target cannot be compared with a quarterly or TTM observation. Aug 18, 202610,671,000,000,000 KRW · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
The evidence does not establish whether SKHY is a durable compounder, cyclical business, or another investment type. Its long-term thesis is insufficiently supported, and the overall evidence confidence is low.
The snapshot provides no valuation comparison or specific market expectations, so it is not possible to describe SKHY as cheap, fair, or expensive versus peers. No fragility gates fired, but that does not establish what the market already assumes.
There is too little recent financial-performance history to assess SKHY’s fundamental trajectory. Near-term miss risk is described as low, but recent earnings surprises have been erratic and industry peers have been missing. Overall risk has risen from moderate to elevated.
Near term, a shift toward Fed rate cuts or steadier results and guidance from major technology peers could support the sector backdrop. Materially slower GDP growth, below the current 2.1%, could weigh more heavily on growth-sensitive technology names. The evidence does not show how specifically these factors affect SKHY.
For the next one to three years, SKHY’s long-term thesis is difficult to assess because business performance and valuation evidence are limited, while risk is elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Profit margins are expected to remain healthy as the company invests in R&D and partnerships. |
| Intact |
| falls below 12% in FY26 |
Net margin: 118.28% FY2026-Q2; GAAP. Published target: >=15%. Annual target cannot be compared with a quarterly or TTM observation. Aug 18, 2026118.282551 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to about $358 billion in FY26 | Revenue is projected to grow to about $358 billion in FY26. | Intact | falls below $340 billion in FY26 | Revenue: KRW 79,318.746B FY2026-Q2; GAAP. Published target: >=358 billion. Annual target cannot be compared with a quarterly or TTM observation. Aug 18, 202679,318,746,000,000 KRW · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$46348.56 → $53281.43 · observed estimates
$514476.61B → $582850.65B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-28 | $46348.56 | $514,476,607,501,247 | 6 / 25 |
| 2026-09-29 | $46639.71 | $517,676,595,825,586 | 6 / 25 |
| 2026-09-30 | $46488.57 | $515,402,520,929,688 | 6 / 26 |
| 2026-10-01 | $46530.09 | $516,669,404,105,948 | 6 / 26 |
| 2026-10-02 | $46426.64 | $515,520,646,004,784 | 6 / 26 |
| 2026-10-03 | $46377.43 | $515,399,404,130,581 | 6 / 26 |
| 2026-10-04 | $46315.78 | $514,714,264,155,356 | 6 / 26 |
| 2026-10-05 | $46321.49 | $514,777,737,729,431 | 6 / 26 |
| 2026-10-06 | $46371.81 | $515,336,343,354,855 | 6 / 26 |
| 2026-10-07 | $46503.48 | $515,797,747,908,007 | 6 / 26 |
| 2026-10-08 | $46644.57 | $516,334,778,762,596 | 6 / 26 |
| 2026-10-09 | $46644.57 | $516,334,778,762,596 | 6 / 26 |
| 2026-10-10 | $46644.57 | $516,334,778,762,596 | 6 / 26 |
| 2026-10-11 | $46858.87 | $519,528,715,070,125 | 6 / 26 |
| 2026-10-12 | $46802.65 | $518,905,411,038,249 | 6 / 26 |
| 2026-10-13 | $46875.41 | $519,086,910,025,473 | 6 / 26 |
| 2026-10-14 | $46880.33 | $518,483,801,790,793 | 6 / 26 |
| 2026-10-15 | $46698.45 | $516,472,266,485,713 | 6 / 26 |
| 2026-10-16 | $46726.21 | $516,787,601,459,661 | 6 / 26 |
| 2026-10-17 | $46726.21 | $516,787,601,459,661 | 6 / 26 |
| 2026-10-18 | $46685.24 | $516,547,143,146,056 | 6 / 26 |
| 2026-10-19 | $46685.24 | $516,547,143,146,056 | 6 / 26 |
| 2026-10-20 | $46836.70 | $517,844,825,760,658 | 6 / 26 |
| 2026-10-21 | $46836.70 | $517,844,825,760,658 | 6 / 26 |
| 2026-10-22 | $46836.70 | $517,891,767,935,570 | 6 / 26 |
| 2026-10-23 | $46843.19 | $517,956,269,298,487 | 6 / 26 |
| 2026-10-24 | $46843.19 | $517,956,269,298,487 | 6 / 26 |
| 2026-10-25 | $46873.16 | $518,289,148,434,823 | 6 / 26 |
| 2026-10-26 | $46873.16 | $518,289,148,434,823 | 6 / 26 |
| 2026-10-27 | $46873.16 | $518,289,148,434,823 | 6 / 26 |
| 2026-10-28 | $47039.67 | $520,976,156,726,134 | 6 / 26 |
| 2026-10-29 | $51820.37 | $566,617,957,611,117 | 6 / 26 |
| 2026-10-30 | $52350.36 | $573,716,761,434,528 | 6 / 26 |
| 2026-10-31 | $53046.82 | $580,092,810,481,301 | 6 / 26 |
| 2026-11-01 | $53078.65 | $580,428,426,304,515 | 6 / 26 |
| 2026-11-02 | $53078.65 | $580,428,426,304,515 | 6 / 26 |
| 2026-11-03 | $53078.65 | $580,428,426,304,515 | 6 / 26 |
| 2026-11-04 | $53281.43 | $582,850,652,704,082 | 6 / 26 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 14 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 5 recorded
1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.